查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1926855

脑脊髓液分流系统市场按产品类型、分流途径、适应症、年龄层和最终用户划分 - 全球预测 2026-2032 年

Cerebrospinal Fluid Shunt System Market by Product Type, Shunt Placement Route, Indication, Age Group, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 198 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2025 年脑脊髓液分流系统市值为 9.2332 亿美元，预计到 2026 年将成长至 9.7343 亿美元，到 2032 年预计将达到 13.7721 亿美元，复合年增长率为 5.87%。

关键市场统计数据
基准年 2025 9.2332亿美元
预计年份：2026年 9.7343亿美元
预测年份 2032 13.7721亿美元
复合年增长率 (%) 5.87%

对现代脑脊髓液分流系统的临床意义、器械类别和战略考虑进行全面概述

本执行摘要概述了脑脊髓液分流系统的临床、技术和商业性现状，并从临床需求、器材创新和不断发展的治疗路径等方面分析了市场格局。脑脊髓液分流仍是治疗方法水脑症及相关疾病的关键方法，支持分流器设计、植入技术和术后管理的生态系统已日趋成熟。因此，从医疗设备製造商到医院和专科诊所等相关人员必须考虑许多因素，包括临床证据、复杂的监管规定以及不断变化的采购重点。

设备创新、诊疗路径重塑和监管收紧将如何重新定义分流系统的竞争优势和临床应用？

由于器械工程技术的进步、医疗数位化以及对长期治疗效果日益重视，脑脊髓液分流系统正在经历变革性的变化。阀门精度和可调节性的提高减少了部分术后併发症的发生，而影像学和术中导航技术的进步则改进了留置技术。这些技术和流程的进步提高了神经外科医师对器械可靠性、术中柔软性和术后可调节性的期望。

评估2025年美国关税环境如何重塑分流系统价值链中的采购选择、采购惯例和长期供应商伙伴关係。

2025年美国关税的累积影响为脑脊髓液分流系统供应链带来了成本压力，并促使各企业重新评估策略。关税相关的到岸成本上涨正促使製造商重新评估筹资策略、生产基地和定价方法。传统上依赖跨境零件采购的企业正在加快供应商资质认证计划，并探索本地製造或组装方案，以降低贸易壁垒和汇率波动带来的风险。

将产品架构、市场定位途径、临床适应症、护理环境和患者人口统计特征与策略研发和商业化决策联繫起来的详细細項分析

对市场区隔的深入理解揭示了临床需求与设备功能相交的领域，以及商业性机会的汇聚点。根据产品类型，市场可分为回流预防装置、非可程式阀和可程式阀。非可程式阀又可细分为差压阀和流量控制阀技术，而可程式阀则可细分为液压可程式阀和磁控阀。这些区分至关重要，因为阀门结构的选择会影响术中决策、术后管理负担以及采购方为证明其应用合理性所需的证据类型。

美洲、欧洲、中东和非洲以及亚太地区的区域监管差异、采购惯例和临床基础设施将如何影响疫苗的采纳、证据需求和打入市场策略？

区域趋势对监管路径、采购行为和技术采纳曲线有显着影响，在製定市场进入和扩大策略时必须考虑。美洲地区先进瓣膜技术的临床应用十分活跃，并且高度重视实证采购。大规模医院系统和专科医疗中心往往是推动对具有术中和术后柔软性的器械需求的主要力量。报销机制和机构采购惯例倾向于那些已被证实能够降低再入院率和再次手术率的解决方案，从而影响着製造商的价值提案和伙伴关係模式。

使市场领先公司脱颖而出的策略行动和能力涵盖了从设备创新和临床证据生成到培训基础设施和策略伙伴关係等各个方面。

脑脊髓液分流系统领域的竞争格局体现为产品创新、服务拓展和策略联盟的融合。业界领导者透过不断改进现有设备、加强上市后监测以及开展临床医生互动项目，来维繫现有基本客群并为其高价产品提供合理依据。新参与企业则倾向于专注于特定领域的优势，例如简化植入流程、降低製造复杂性，或针对特定适应症或年龄层的临床疗效。

製造商和供应商可采取的切实可行的策略重点，以增强临床可靠性、供应链韧性和持续的商业性优势。

产业领导者应采取平衡策略，在加速创新的同时，增强临床可靠性和供应链韧性。优先投资于可程式设计和可调节瓣膜技术，这些技术已被证实能够降低再次手术率，并满足外科医生术中操作柔软性的需求；同时，还应投资于完善的上市后数据收集，以检验长期疗效。此外，还应透过全面的临床医生培训计划和模拟资源来完善产品开发，从而缩短学习曲线，并在不同的临床环境中实现植入技术的标准化。

一项透明的混合用途研究设计整合了临床医生访谈、监管审查、临床註册分析和情境建模，以确保研究结果的可靠检验。

本报告的调查方法融合了多种定性和定量方法，以确保整体性和可靠性。主要研究包括对来自不同临床环境的神经外科医生、采购主管和临床专案经理进行结构化访谈，以了解他们在实际应用中对器械的选择偏好、手术流程方面的考虑以及实施过程中遇到的障碍。透过与这些相关人员的对话，以及与监管和报销专家的深入探讨，我们绘製了不同地区的核准途径和支付方预期。

关于创新、证据生成和供应链实力如何协调一致，将决定分流系统的长期成功和临床影响的关键发现

总之，脑脊髓液分流系统领域正处于一个转折点，器械工程、不断发展的临床实践和商业性压力正在汇聚，重塑其市场推广动态。对可调节和耐用阀门技术的重视、对真实世界证据的需求以及供应链可预测性，意味着成功的企业必须整合技术创新、卓越营运和相关人员参与。临床需求依然是核心，能够减少併发症并提高术后管理效率的器械将受到采购者的优先考虑。

目录

第一章：序言

第二章调查方法

  • 研究设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查前提
  • 调查限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会地图
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 脑脊髓液分流系统市场（依产品类型划分）

  • 回流防止装置
  • 非可程式阀门
    • 差压阀
    • 流量控制阀
  • 可程式阀
    • 液压可程式阀
    • 磁力调节阀

9. 脑脊髓液分流系统市场（依分流器安装途径划分）

  • 腰椎分流术
  • 腰椎-腹膜分流术
  • 心室心房分流术
  • 脑室腹腔分流术

10. 脑脊髓液分流系统市场（依适应症划分）

  • 交通性水脑症
  • 非交通性水脑症
  • 正常水脑症

第十一章 脑脊髓液分流系统市场（依年龄组别划分）

  • 成人版
  • 老年人
  • 儿童

12. 脑脊髓液分流系统市场（依最终用户划分）

  • 门诊手术中心
  • 医院
  • 专科诊所

13. 脑脊髓液分流系统市场（依地区划分）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

14. 脑脊髓液分流系统市场（依组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

15. 各国脑脊髓液分流系统市场

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

16. 美国脑脊髓液分流系统市场

第十七章：中国脑脊髓液分流系统市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Anuncia Inc.
  • B. Braun Melsungen AG
  • CereVasc, Inc.
  • Christoph Miethke GmbH & Co. KG
  • Delta Surgical
  • Dispomedica GmbH
  • G. Surgiwear Ltd.
  • HpBio Proteses, inc.
  • Integra LifeSciences
  • Kaneka Corporation
  • Medtronic plc
  • Moller Medical GmbH
  • Natus Medical Incorporated
  • Sophysa
  • Spiegelberg GmbH & Co. KG
Product Code: MRR-4F7A6D4FF338

The Cerebrospinal Fluid Shunt System Market was valued at USD 923.32 million in 2025 and is projected to grow to USD 973.43 million in 2026, with a CAGR of 5.87%, reaching USD 1,377.21 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 923.32 million
Estimated Year [2026] USD 973.43 million
Forecast Year [2032] USD 1,377.21 million
CAGR (%) 5.87%

Comprehensive orientation to the clinical importance, device categories, and strategic considerations shaping modern cerebrospinal fluid shunt systems

This executive summary introduces the clinical, technological, and commercial landscape surrounding cerebrospinal fluid shunt systems, framing the market through clinical need, device innovation, and care pathway evolution. Cerebrospinal fluid diversion remains a cornerstone intervention for hydrocephalus and related indications, and the ecosystem supporting shunt design, implantation techniques, and postoperative management has matured considerably. As a result, stakeholders from device manufacturers to hospitals and specialty clinics must navigate a mix of clinical evidence, regulatory complexity, and shifting procurement priorities.

The introduction clarifies core device categories and clinical contexts without presupposing prior knowledge, enabling readers to quickly orient to what matters most for strategy and investment. It emphasizes how product design decisions intersect with procedural trends, device lifecycle considerations, and the need for robust outcomes data. This section also previews the downstream chapters that unpack regulatory pressures, trade dynamics, segmentation nuance, regional drivers, competitive behavior, and actionable recommendations.

Throughout, the tone is analytical and pragmatic: the goal is to arm clinical leaders, commercial strategists, and procurement teams with a concise but comprehensive orientation that supports informed decisions about portfolio positioning, R&D priorities, and channel engagement. By establishing this baseline understanding, readers will be prepared to evaluate the more granular findings and strategic recommendations that follow.

How device innovation, care pathway redesign, and regulatory rigor are redefining competitive advantage and clinical adoption for shunt systems

The landscape for cerebrospinal fluid shunt systems has undergone transformative shifts driven by advances in device engineering, digitization of care, and heightened emphasis on long-term outcomes. Improvements in valve precision and adjustable mechanisms have reduced some sources of postoperative morbidity, and concurrent developments in imaging and intraoperative navigation have refined placement techniques. These technological and procedural advances have created new expectations among neurosurgeons for device reliability, intraoperative flexibility, and postoperative adjustability.

Meanwhile, clinical pathways are changing as multidisciplinary teams incorporate enhanced recovery protocols and outpatient management models to shorten hospital stays and reduce complications. Payers and providers increasingly demand evidence of durable benefit and lower total cost of care, elevating the importance of longitudinal clinical evidence and real-world data collection. This has prompted manufacturers to invest not only in device performance but also in post-market surveillance, registries, and patient support programs that document outcomes and facilitate device optimization over time.

Supply chain resilience and regulatory scrutiny have also shifted priorities. Manufacturers are exploring design-for-manufacture approaches and supply diversification to mitigate disruption risk. On the regulatory front, authorities are tightening expectations for clinical validation, which in turn influences product development timelines and market entry strategies. Taken together, these forces are reconfiguring competitive dynamics and raising the bar for market entrants while offering incumbents opportunities to differentiate through data-driven value propositions and service-based offerings.

Assessing how the 2025 United States tariff environment has reshaped sourcing choices, procurement practices, and long-term supplier partnerships across the shunt system value chain

The cumulative effect of tariffs implemented in the United States in 2025 has introduced cost pressures and strategic recalibrations across the cerebrospinal fluid shunt system supply chain. Tariff-related increases in landed costs have incentivized manufacturers to reassess sourcing strategies, production footprints, and pricing approaches. Organizations that traditionally relied on cross-border component sourcing have accelerated supplier qualification programs and explored regional manufacturing or assembly options to reduce exposure to trade barriers and currency volatility.

These shifts have also influenced procurement behavior at institutional and group purchasing organization levels, where total cost of ownership models now explicitly incorporate tariff-related cost variability. Hospitals and ambulatory centers are negotiating tighter contract terms and seeking longer-term price protections, while some purchasers are prioritizing devices with proven durability to offset near-term cost increases. In parallel, manufacturers are responding by emphasizing differentiated clinical value and by offering bundled service packages and training that aim to justify premium pricing in the face of higher input costs.

Regulatory conformity and customs compliance have become operational priorities; companies are investing in enhanced trade compliance capabilities and scenario planning to ensure uninterrupted supply of critical components. Overall, the 2025 tariff environment has prompted a shift from cost-minimization through global sourcing toward a hybrid model that balances cost, control, and continuity, altering how stakeholders evaluate vendor relationships and long-term partnership structures.

Deep segmentation analysis that connects product architecture, placement routes, clinical indications, care settings, and patient age groups to strategic R&D and commercialization decisions

A granular understanding of segmentation reveals where clinical needs intersect with device capability and where commercial opportunities concentrate. Based on product type, the market encompasses anti-siphon devices, non-programmable valves, and programmable valves, with non-programmable variants further distinguished into differential pressure and flow regulating valve technologies and programmable options subdivided into hydraulic programmable and magnetic adjustable designs. These distinctions matter because the choice of valve architecture affects intraoperative decision-making, postoperative management burden, and the types of evidence purchasers require to justify adoption.

Based on shunt placement route, clinical practice differentiates lumbar shunt, lumbo peritoneal shunt, ventriculo atrial shunt, and ventriculo peritoneal shunt approaches, each presenting unique technical demands and complication profiles that influence product design preferences and training needs. Based on end user, the device adoption landscape spans ambulatory surgical centers, hospitals, and specialty clinics, with variations in procedural volume, surgical expertise, and purchasing governance shaping demand and support requirements. Based on indication, clinical categories include communicating hydrocephalus, non-communicating hydrocephalus, and normal pressure hydrocephalus, and each indication drives specific expectations around outcomes, patient selection criteria, and follow-up care.

Based on age group, patient segments of adult, geriatric, and pediatric populations present distinct anatomical, physiological, and device-longevity considerations that influence both clinical decision-making and product lifecycle planning. Integrating these segmentation lenses clarifies how value propositions should be tailored: pediatric programs may prioritize growth-accommodation and longevity, geriatric pathways emphasize minimally invasive approaches and comorbidity management, and programmable valve adoption often aligns with centers that can support longitudinal follow-up and adjustment capabilities. By mapping product design to placement route, end user, indication, and age group, stakeholders can better align R&D investment, clinical support services, and commercialization tactics to real-world needs.

How regional regulatory diversity, procurement practices, and clinical infrastructure in the Americas, EMEA, and Asia-Pacific determine adoption, evidence needs, and go-to-market tactics

Regional dynamics exert significant influence on regulatory pathways, purchasing behavior, and technology adoption curves and must be considered when prioritizing market entry and expansion strategies. The Americas region exhibits robust clinical adoption of advanced valve technologies and an emphasis on evidence-based purchasing, with large hospital systems and specialty centers often driving demand for devices that offer adjustable intraoperative and postoperative flexibility. Reimbursement structures and institutional procurement practices tend to favor solutions that demonstrably lower readmission and revision rates, which shapes manufacturer value propositions and partnership models.

Europe, Middle East & Africa presents a heterogeneous landscape where regulatory frameworks and healthcare financing models vary markedly across countries. In some European markets, centralized procurement and stringent clinical evaluation foster adoption of devices supported by strong clinical registries and cost-effectiveness analyses. In parts of the Middle East and Africa, demand is influenced by infrastructure constraints, training availability, and the need for robust, easy-to-deploy solutions that perform reliably in diverse clinical environments.

Asia-Pacific combines high-growth pockets with established referral centers that rapidly adopt novel technologies alongside markets where cost containment and supply chain considerations dominate purchasing decisions. Local manufacturing capacity, regulatory timelines, and national-level healthcare investments strongly affect go-to-market strategies. Across all regions, manufacturers must tailor clinical evidence packages, service models, and pricing approaches to accommodate distinct regulatory expectations, care delivery contexts, and procurement norms.

Strategic behaviors and capabilities that differentiate market leaders, from device innovation and clinical evidence generation to training infrastructure and strategic partnerships

Competitive behavior within the cerebrospinal fluid shunt system arena reflects a blend of product innovation, service augmentation, and strategic partnership. Industry leaders leverage a combination of incremental device improvements, strengthened post-market surveillance, and clinician engagement programs to defend installed bases and justify premium pricing. Newer entrants often focus on niche advantages such as simplified implantation workflows, lower manufacturing complexity, or targeted clinical claims that resonate within specific indication or age-group segments.

Companies that succeed over the medium term typically combine technical differentiation with robust clinical data generation and scalable training infrastructure. Investments in surgeon education, simulation-based training, and localized clinical support reduce variability in outcomes and accelerate adoption. In addition, firms that develop digital tools for remote monitoring, postoperative adjustment tracking, and registry participation can create enduring ties with providers and patients, translating product performance into measurable health system benefits.

Partnership strategies also emerge as a differentiator. Collaboration with centers of excellence for registry development, alliance-building with regional distributors for market access, and strategic collaborations with academic groups for long-term outcomes research all help firms bolster credibility and create defensible market positions. Financial discipline, supply chain resilience, and regulatory foresight round out the profile of companies positioned to lead amid evolving clinical and commercial expectations.

Practical strategic priorities for manufacturers and providers to strengthen clinical credibility, supply chain resilience, and sustained commercial advantage

Industry leaders should pursue a balanced strategy that accelerates innovation while reinforcing clinical credibility and supply chain resilience. Prioritize investments in programmable and adjustable valve technologies that demonstrably reduce revision rates and support surgeon preference for intraoperative flexibility, while simultaneously investing in robust post-market data collection to validate long-term outcomes. Complement product development with comprehensive clinician training programs and simulation resources to reduce learning curves and standardize implantation technique across diverse care settings.

Mitigate trade-related cost volatility by diversifying component sourcing and considering regional assembly or manufacturing partnerships that lower exposure to tariff fluctuations. Strengthen trade compliance and scenario planning capacities so that procurement teams can respond quickly to policy changes without compromising supply continuity. To address payer scrutiny and procurement demands, develop articulate value dossiers that link device performance to patient-centric outcomes and total cost of care metrics, and be prepared to support local health economic modeling when required by large institutions or health systems.

Finally, cultivate collaborative relationships with leading clinical centers to generate registry-grade evidence and develop patient support services that increase adherence to follow-up protocols. Such partnerships can amplify real-world evidence generation and create a defensible narrative around safety and efficacy. By aligning product innovation, evidence generation, supply chain agility, and clinician engagement, industry players can sustain competitive advantage and deliver measurable clinical value to health systems and patients.

Transparent mixed-methods research design integrating clinician interviews, regulatory review, clinical registry analysis, and scenario modeling for robust validation of findings

The research methodology underpinning this report integrates multiple qualitative and quantitative approaches to ensure comprehensiveness and credibility. Primary research comprised structured interviews with neurosurgeons, procurement leaders, and clinical program managers across diverse care settings to surface real-world device preferences, procedural considerations, and adoption barriers. These stakeholder engagements were complemented by in-depth discussions with regulatory and reimbursement experts to map approval pathways and payer expectations across regions.

Secondary research included systematic review of peer-reviewed clinical literature, regulatory filings, and device labeling to corroborate efficacy and safety profiles. Publicly available clinical registries and hospital procedural databases were consulted to understand practice patterns and complication profiles, while technical specifications and instructions for use informed device feature comparisons. The triangulation of primary insights and secondary evidence enabled robust cross-validation of trends, clinical priorities, and commercial behaviors.

Analytical techniques applied included thematic synthesis of clinician interviews to identify unmet needs, comparative feature mapping across device architectures, and scenario analysis to evaluate the commercial implications of supply chain and policy shifts. Throughout the process, data integrity protocols were followed to ensure source traceability and to minimize bias. The methodology emphasizes transparency and reproducibility, enabling stakeholders to understand how conclusions were derived and to replicate key analyses as needed.

Key conclusions on how aligned innovation, evidence generation, and supply chain strength will determine long-term success and clinical impact in shunt systems

In conclusion, the cerebrospinal fluid shunt system domain is at an inflection point where device engineering, clinical practice evolution, and commercial pressures converge to reshape adoption dynamics. The emphasis on adjustable and durable valve technologies, coupled with demands for real-world evidence and supply chain predictability, means that successful organizations will need to integrate technical innovation with operational excellence and stakeholder engagement. Clinical needs remain central, and devices that reduce complications and enable efficient postoperative management will command priority among purchasers.

Looking ahead, manufacturers that can demonstrate clear improvements in patient outcomes while offering reliable service models and adaptive sourcing strategies will be best positioned to capture sustained demand. Providers and procurement leaders should seek partners that offer not only differentiated devices but also data, training, and support that lower institutional risk. Regulators and payers will continue to influence development trajectories by requiring higher levels of evidence and by recognizing technologies that contribute to overall system efficiency.

Ultimately, the path to meaningful impact lies in aligning product capabilities with clinical workflows, evidence generation, and resilient commercial models that together enhance patient care while meeting the operational needs of modern health systems.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Cerebrospinal Fluid Shunt System Market, by Product Type

  • 8.1. Anti-Siphon Device
  • 8.2. Non-Programmable Valve
    • 8.2.1. Differential Pressure Valve
    • 8.2.2. Flow Regulating Valve
  • 8.3. Programmable Valve
    • 8.3.1. Hydraulic Programmable Valve
    • 8.3.2. Magnetic Adjustable Valve

9. Cerebrospinal Fluid Shunt System Market, by Shunt Placement Route

  • 9.1. Lumbar Shunt
  • 9.2. Lumbo Peritoneal Shunt
  • 9.3. Ventriculo Atrial Shunt
  • 9.4. Ventriculo Peritoneal Shunt

10. Cerebrospinal Fluid Shunt System Market, by Indication

  • 10.1. Communicating Hydrocephalus
  • 10.2. Non-Communicating Hydrocephalus
  • 10.3. Normal Pressure Hydrocephalus

11. Cerebrospinal Fluid Shunt System Market, by Age Group

  • 11.1. Adult
  • 11.2. Geriatric
  • 11.3. Pediatric

12. Cerebrospinal Fluid Shunt System Market, by End User

  • 12.1. Ambulatory Surgical Center
  • 12.2. Hospitals
  • 12.3. Specialty Clinic

13. Cerebrospinal Fluid Shunt System Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Cerebrospinal Fluid Shunt System Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Cerebrospinal Fluid Shunt System Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Cerebrospinal Fluid Shunt System Market

17. China Cerebrospinal Fluid Shunt System Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Anuncia Inc.
  • 18.6. B. Braun Melsungen AG
  • 18.7. CereVasc, Inc.
  • 18.8. Christoph Miethke GmbH & Co. KG
  • 18.9. Delta Surgical
  • 18.10. Dispomedica GmbH
  • 18.11. G. Surgiwear Ltd.
  • 18.12. HpBio Proteses, inc.
  • 18.13. Integra LifeSciences
  • 18.14. Kaneka Corporation
  • 18.15. Medtronic plc
  • 18.16. Moller Medical GmbH
  • 18.17. Natus Medical Incorporated
  • 18.18. Sophysa
  • 18.19. Spiegelberg GmbH & Co. KG

LIST OF FIGURES

  • FIGURE 1. GLOBAL CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL CEREBROSPINAL FLUID SHUNT SYSTEM MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, BY SHUNT PLACEMENT ROUTE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, BY AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, BY ANTI-SIPHON DEVICE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, BY ANTI-SIPHON DEVICE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, BY ANTI-SIPHON DEVICE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, BY NON-PROGRAMMABLE VALVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, BY NON-PROGRAMMABLE VALVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, BY NON-PROGRAMMABLE VALVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, BY NON-PROGRAMMABLE VALVE, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, BY DIFFERENTIAL PRESSURE VALVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, BY DIFFERENTIAL PRESSURE VALVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, BY DIFFERENTIAL PRESSURE VALVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, BY FLOW REGULATING VALVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, BY FLOW REGULATING VALVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, BY FLOW REGULATING VALVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, BY PROGRAMMABLE VALVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, BY PROGRAMMABLE VALVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, BY PROGRAMMABLE VALVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, BY PROGRAMMABLE VALVE, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, BY HYDRAULIC PROGRAMMABLE VALVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, BY HYDRAULIC PROGRAMMABLE VALVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, BY HYDRAULIC PROGRAMMABLE VALVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, BY MAGNETIC ADJUSTABLE VALVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, BY MAGNETIC ADJUSTABLE VALVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, BY MAGNETIC ADJUSTABLE VALVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, BY SHUNT PLACEMENT ROUTE, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, BY LUMBAR SHUNT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, BY LUMBAR SHUNT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, BY LUMBAR SHUNT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, BY LUMBO PERITONEAL SHUNT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, BY LUMBO PERITONEAL SHUNT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, BY LUMBO PERITONEAL SHUNT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, BY VENTRICULO ATRIAL SHUNT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, BY VENTRICULO ATRIAL SHUNT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, BY VENTRICULO ATRIAL SHUNT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, BY VENTRICULO PERITONEAL SHUNT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, BY VENTRICULO PERITONEAL SHUNT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, BY VENTRICULO PERITONEAL SHUNT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, BY COMMUNICATING HYDROCEPHALUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, BY COMMUNICATING HYDROCEPHALUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, BY COMMUNICATING HYDROCEPHALUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, BY NON-COMMUNICATING HYDROCEPHALUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, BY NON-COMMUNICATING HYDROCEPHALUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, BY NON-COMMUNICATING HYDROCEPHALUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, BY NORMAL PRESSURE HYDROCEPHALUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, BY NORMAL PRESSURE HYDROCEPHALUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, BY NORMAL PRESSURE HYDROCEPHALUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, BY ADULT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, BY ADULT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, BY GERIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, BY AMBULATORY SURGICAL CENTER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, BY AMBULATORY SURGICAL CENTER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, BY AMBULATORY SURGICAL CENTER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, BY SPECIALTY CLINIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, BY SPECIALTY CLINIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, BY SPECIALTY CLINIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. AMERICAS CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 71. AMERICAS CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 72. AMERICAS CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, BY NON-PROGRAMMABLE VALVE, 2018-2032 (USD MILLION)
  • TABLE 73. AMERICAS CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, BY PROGRAMMABLE VALVE, 2018-2032 (USD MILLION)
  • TABLE 74. AMERICAS CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, BY SHUNT PLACEMENT ROUTE, 2018-2032 (USD MILLION)
  • TABLE 75. AMERICAS CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 76. AMERICAS CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. AMERICAS CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 78. NORTH AMERICA CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. NORTH AMERICA CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 80. NORTH AMERICA CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, BY NON-PROGRAMMABLE VALVE, 2018-2032 (USD MILLION)
  • TABLE 81. NORTH AMERICA CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, BY PROGRAMMABLE VALVE, 2018-2032 (USD MILLION)
  • TABLE 82. NORTH AMERICA CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, BY SHUNT PLACEMENT ROUTE, 2018-2032 (USD MILLION)
  • TABLE 83. NORTH AMERICA CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 84. NORTH AMERICA CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. NORTH AMERICA CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 86. LATIN AMERICA CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. LATIN AMERICA CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 88. LATIN AMERICA CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, BY NON-PROGRAMMABLE VALVE, 2018-2032 (USD MILLION)
  • TABLE 89. LATIN AMERICA CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, BY PROGRAMMABLE VALVE, 2018-2032 (USD MILLION)
  • TABLE 90. LATIN AMERICA CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, BY SHUNT PLACEMENT ROUTE, 2018-2032 (USD MILLION)
  • TABLE 91. LATIN AMERICA CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 92. LATIN AMERICA CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. LATIN AMERICA CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPE, MIDDLE EAST & AFRICA CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPE, MIDDLE EAST & AFRICA CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPE, MIDDLE EAST & AFRICA CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, BY NON-PROGRAMMABLE VALVE, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE, MIDDLE EAST & AFRICA CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, BY PROGRAMMABLE VALVE, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE, MIDDLE EAST & AFRICA CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, BY SHUNT PLACEMENT ROUTE, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE, MIDDLE EAST & AFRICA CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE, MIDDLE EAST & AFRICA CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, BY NON-PROGRAMMABLE VALVE, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, BY PROGRAMMABLE VALVE, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, BY SHUNT PLACEMENT ROUTE, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 110. MIDDLE EAST CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. MIDDLE EAST CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 112. MIDDLE EAST CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, BY NON-PROGRAMMABLE VALVE, 2018-2032 (USD MILLION)
  • TABLE 113. MIDDLE EAST CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, BY PROGRAMMABLE VALVE, 2018-2032 (USD MILLION)
  • TABLE 114. MIDDLE EAST CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, BY SHUNT PLACEMENT ROUTE, 2018-2032 (USD MILLION)
  • TABLE 115. MIDDLE EAST CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 116. MIDDLE EAST CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 117. MIDDLE EAST CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 118. AFRICA CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 119. AFRICA CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 120. AFRICA CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, BY NON-PROGRAMMABLE VALVE, 2018-2032 (USD MILLION)
  • TABLE 121. AFRICA CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, BY PROGRAMMABLE VALVE, 2018-2032 (USD MILLION)
  • TABLE 122. AFRICA CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, BY SHUNT PLACEMENT ROUTE, 2018-2032 (USD MILLION)
  • TABLE 123. AFRICA CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 124. AFRICA CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 125. AFRICA CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 126. ASIA-PACIFIC CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. ASIA-PACIFIC CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 128. ASIA-PACIFIC CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, BY NON-PROGRAMMABLE VALVE, 2018-2032 (USD MILLION)
  • TABLE 129. ASIA-PACIFIC CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, BY PROGRAMMABLE VALVE, 2018-2032 (USD MILLION)
  • TABLE 130. ASIA-PACIFIC CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, BY SHUNT PLACEMENT ROUTE, 2018-2032 (USD MILLION)
  • TABLE 131. ASIA-PACIFIC CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 132. ASIA-PACIFIC CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 133. ASIA-PACIFIC CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 135. ASEAN CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. ASEAN CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 137. ASEAN CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, BY NON-PROGRAMMABLE VALVE, 2018-2032 (USD MILLION)
  • TABLE 138. ASEAN CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, BY PROGRAMMABLE VALVE, 2018-2032 (USD MILLION)
  • TABLE 139. ASEAN CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, BY SHUNT PLACEMENT ROUTE, 2018-2032 (USD MILLION)
  • TABLE 140. ASEAN CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 141. ASEAN CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 142. ASEAN CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 143. GCC CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. GCC CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 145. GCC CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, BY NON-PROGRAMMABLE VALVE, 2018-2032 (USD MILLION)
  • TABLE 146. GCC CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, BY PROGRAMMABLE VALVE, 2018-2032 (USD MILLION)
  • TABLE 147. GCC CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, BY SHUNT PLACEMENT ROUTE, 2018-2032 (USD MILLION)
  • TABLE 148. GCC CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 149. GCC CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 150. GCC CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPEAN UNION CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPEAN UNION CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPEAN UNION CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, BY NON-PROGRAMMABLE VALVE, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPEAN UNION CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, BY PROGRAMMABLE VALVE, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPEAN UNION CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, BY SHUNT PLACEMENT ROUTE, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPEAN UNION CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPEAN UNION CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPEAN UNION CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 159. BRICS CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 160. BRICS CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 161. BRICS CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, BY NON-PROGRAMMABLE VALVE, 2018-2032 (USD MILLION)
  • TABLE 162. BRICS CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, BY PROGRAMMABLE VALVE, 2018-2032 (USD MILLION)
  • TABLE 163. BRICS CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, BY SHUNT PLACEMENT ROUTE, 2018-2032 (USD MILLION)
  • TABLE 164. BRICS CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 165. BRICS CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 166. BRICS CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 167. G7 CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 168. G7 CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 169. G7 CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, BY NON-PROGRAMMABLE VALVE, 2018-2032 (USD MILLION)
  • TABLE 170. G7 CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, BY PROGRAMMABLE VALVE, 2018-2032 (USD MILLION)
  • TABLE 171. G7 CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, BY SHUNT PLACEMENT ROUTE, 2018-2032 (USD MILLION)
  • TABLE 172. G7 CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 173. G7 CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 174. G7 CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 175. NATO CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 176. NATO CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 177. NATO CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, BY NON-PROGRAMMABLE VALVE, 2018-2032 (USD MILLION)
  • TABLE 178. NATO CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, BY PROGRAMMABLE VALVE, 2018-2032 (USD MILLION)
  • TABLE 179. NATO CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, BY SHUNT PLACEMENT ROUTE, 2018-2032 (USD MILLION)
  • TABLE 180. NATO CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 181. NATO CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 182. NATO CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 183. GLOBAL CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 184. UNITED STATES CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 185. UNITED STATES CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 186. UNITED STATES CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, BY NON-PROGRAMMABLE VALVE, 2018-2032 (USD MILLION)
  • TABLE 187. UNITED STATES CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, BY PROGRAMMABLE VALVE, 2018-2032 (USD MILLION)
  • TABLE 188. UNITED STATES CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, BY SHUNT PLACEMENT ROUTE, 2018-2032 (USD MILLION)
  • TABLE 189. UNITED STATES CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 190. UNITED STATES CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 191. UNITED STATES CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 192. CHINA CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 193. CHINA CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 194. CHINA CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, BY NON-PROGRAMMABLE VALVE, 2018-2032 (USD MILLION)
  • TABLE 195. CHINA CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, BY PROGRAMMABLE VALVE, 2018-2032 (USD MILLION)
  • TABLE 196. CHINA CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, BY SHUNT PLACEMENT ROUTE, 2018-2032 (USD MILLION)
  • TABLE 197. CHINA CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 198. CHINA CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 199. CHINA CEREBROSPINAL FLUID SHUNT SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)